<p>Significantly fewer adverse reactions reported by those in the cytisine group versus the varenicline group</p>
<p>Lisdexamfetamine found to reduce symptoms of sluggish cognitive tempo in small group of adults with ADHD</p>
<p>Donanemab has already received a 'breakthrough therapy' designation from the FDA</p>
<p>No significant differences in language development seen at age 2 years for children born to mothers with epilepsy</p>
<p>ADHD medications may moderate the association between externalizing symptoms and risk for suicidality in children</p>
<p>Less than 5 percent of prescribers account for half of all buprenorphine treatment in the country</p>
<p>Patients report side effects, beliefs, and knowledge about bipolar disorder are top reasons for not taking medications</p>
<p>Women who initiated sleep medications rated their sleep disturbances similarly after one and two years</p>
<p>Improvement seen in treatment satisfaction and several secondary end points for depot buprenorphine versus sublingual buprenorphine</p>
<p>Symptoms are reduced in a majority of preschool-aged children who initiate therapy with α<sub>2</sub>-adrenergic agonists or stimulants for ADHD</p>